Back
ESC Premium Access

The impact of postprocedural trimetazidine therapy on bare metal stent restenosis in patients undergoing percutaneous coronary intervention

Session: Poster session 4 - Mechanisms of restenosis - Its predictors and treatment
Topic: Restenosis
Speaker: Professor U. Canpolat (Ankara, TR)
Event: ESC Congress 2016

Congress Presentation

About the speaker

Professor Ugur Canpolat

Hacettepe University, Ankara (Türkiye)
1 presentation
0 follower

19 more presentations in this session

Predicting repeat revascularization after percutaneous coronary intervention: target lesion versus nontarget lesion revascularization

Speaker: Professor S. Rha (Seoul, KP)

Access
Abstract
Slides
Thumbnail

Comparison of acute and 1 year outcome of percutaneous coronary intervention for chronic total occlusion lesion between in stent occlusion and de novo lesion from the Japanese retrograde summit regist

Speaker: Doctor S. Ebisawa (Toyohashi, JP)

Access
Abstract
Thumbnail

Anti-inflammatory treatment with colchicine to reduce in-stent neointima growth in patients with drug eluting stents

Speaker: Associate Professor G. Giannopoulos (Thessaloniki, GR)

Access
Abstract
Slides
Thumbnail

Comparison of drug-eluting balloon versus drug-eluting stent treatment of DES in-stent restenosis: a meta-analysis of randomized and observational studies

Speaker: Professor G. Bajraktari (Pristina, XK)

Access
Abstract
Slides
Thumbnail

CTRP 5 links vascular smooth muscle cell proliferation and inflammation to in-stent restenosis after coronary drug-eluting stent implantation

Speaker: Professor W. Shen (Shanghai, CN)

Access
Abstract
Slides
Thumbnail

Access the full session

Poster session 4 - Mechanisms of restenosis - Its predictors and treatment

Speakers: Professor U. Canpolat, Professor S. Rha, Doctor S. Ebisawa, Associate Professor G. Giannopoulos, Professor G. Bajraktari...
Access
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb